Company Appoints Medical Device and Healthcare Industry Veteran with 20 Years of Experience
Lungpacer Medical announced the appointment of Kevin Kearney as Chief Commercial Officer (CCO). Kearney brings over 20 years of commercial leadership, business development, and strategic sales operations experience in the medical device and healthcare industries. His appointment marks a significant milestone as the company expands its footprint and accelerates its mission to transform respiratory and cardiac patient care.
In his role as CCO, Kearney will oversee the commercial strategy for Lungpacer’s AeroPace System, including sales, marketing, business development, and customer engagement efforts. He will help drive company growth and expand its market presence, working closely with the executive team to position Lungpacer for success as a transformative technology in critical care.
Health Technology Insights: PatientIQ Launches DataPRO for Instant Market Insights
“Kevin’s proven track record of leadership and success in commercial operations within the healthcare industry makes him the perfect fit to help us scale and bring our life-changing technologies to more patients worldwide,” said Doug Evans, CEO of Lungpacer Medical. “His deep expertise in building high-performance teams and executing strategic growth initiatives will be invaluable as we continue to drive innovation and impact in respiratory and cardiac patient care.”
Kearney has dedicated his career to helping medical device and healthcare companies advance patient care delivery. Previously, he served as Vice President of Account Management Sales at Ceribell, where he led commercial strategy and significantly contributed to its growth in the neurology and critical care departments. Throughout his career, he has demonstrated exceptional ability to build and lead teams that execute successful go-to-market strategies for innovative products, foster partnerships, and drive substantial revenue growth.
Health Technology Insights: Juniper Communities and NHI Partner on NJ Senior Living
“Lungpacer is at a pivotal point in its journey,” said Kearney. “The company’s commitment to developing innovative interventional therapies that free patients from mechanical ventilation while preserving diaphragm, lung, heart, and brain health, aligns with my passion for improving patient outcomes. I look forward to working with this talented team to advance our mission and expand our impact in the healthcare industry.”
With the commercialization of its recently FDA-approved AeroPace System, a neurostimulation device indicated to increase weaning, reduce ventilator days, and reduce reintubation in patients ages 18 years or older on mechanical ventilation ≥ 96 hours and who have not weaned, Kearney’s leadership will be instrumental in helping Lungpacer scale its operations, build strong customer relationships, and drive sustained growth.
Health Technology Insights: Omeros Updates Phase 3 Zaltenibart PNH Clinical Trial
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
